Ang Cannabidiol (CBD) ang isa sa mga 85 cannabinoid na matatagpuan sa halamang cannabis o marijuana.[5] Ito ang pangunahing sangkap ng halaman na ikalawa sa THC at kumakatawan sa hanggang 40% nito.[6] Kumpara sa THC, ang cannabidiol ay mas kaunting sikoaktibo at itinuturing na may mas malawak na sakop ng mga paggamot medikal kesa sa THC [7] kabilang sa epilepsy,[8] multiple sclerosis spasms,[9] anxiety disorders, bipolar Disorder,[7] schizophrenia,[10] nausea, kombulsiyon at pamamaga gayundin sa pagpigil ng paglago ng selulang kanser.[11] Ang Cannabidiol ay nagpakita ng mga epektong sedatibo, pampakalma sa mga pagsubok sa hayop[12] o kaginhawan ng artritis sa aso.[12] Ang ibang pagsasaliksik ay nagpapakita na ito ay nagpapataas ng pagiging alerto.[13] Ang Cannabidiol ay naipakitang nagbawas ng paglago ng mga selulang kanser sa suso in vitro at nagbawas ng kanilang pagsalakay.[14]
Agarang impormasyon Datos Klinikal, Mga tatak pangkalakal ...
Cannabidiol![Thumb](//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Cannabidiol_Structural_formula_V1.svg/220px-Cannabidiol_Structural_formula_V1.svg.png) |
![Thumb](//upload.wikimedia.org/wikipedia/commons/thumb/e/e1/CBD-3D-balls.png/220px-CBD-3D-balls.png) |
|
Mga tatak pangkalakal | Epidiolex |
---|
AHFS/Drugs.com | International Drug Names |
---|
Kodigong ATC | |
---|
|
Estadong legal |
- AU: S4 (Tanging reseta)
- CA: Iskedyul II
- UK: POM (Tanging reseta) o Suplementong Pangkalusugan
- US: Iskedyul I [1]
|
---|
|
Bioavailability | 13–19% (pambibig),[2] 11–45% (turan 31%; langhap)[3] |
---|
Biyolohikal na hating-buhay | 9 na oras[2] |
---|
|
Pangalang IUPAC
- 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
|
Bilang ng CAS | |
---|
PubChem CID | |
---|
IUPHAR/BPS | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEBI | |
---|
ECHA InfoCard | 100.215.986 |
---|
|
Pormula | C21H30O2 |
---|
Bigat Molar | 314.4636 |
---|
Modelong 3D (Jmol) | |
---|
Punto ng pagkatunaw | 66 °C (151 °F) |
---|
Punto ng pagkulo | 180 °C (356 °F) (hangganan: 160–180 °C)[4] |
---|
SMILES
Oc1c(c(O)cc(c1)CCCCC)[C@@H]2\C=C(/CC[C@H]2\C(=C)C)C
|
InChI
InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h9,12-13,17-18,22-23H,2,5-8,10-11H2,1,3-4H3/t17-,18+/m0/s1 YKey:ZTGXAWYVTLUPDT-ZWKOTPCHSA-N Y
|
|
Isara
DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml Naka-arkibo 2017-01-17 sa Wayback Machine.; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance."). Mechoulam R, Parker LA, Gallily R (Nobyembre 2002). "Cannabidiol: an overview of some pharmacological aspects". J Clin Pharmacol (Review). 42 (11 Suppl): 11S–19S. doi:10.1177/0091270002238789. PMID 12412831.{{cite journal}}
: CS1 maint: date auto-translated (link) Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (Mayo 2009). "Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders". Phytother Res (Review). 23 (5): 597–602. doi:10.1002/ptr.2625. PMID 18844286.{{cite journal}}
: CS1 maint: date auto-translated (link) Ashton, C.H., Moore, P. B., Gallagher, P., Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology (U.K).
McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007). "Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells". Mol. Cancer Ther. 6 (11): 2921–7. doi:10.1158/1535-7163.MCT-07-0371. PMID 18025276.{{cite journal}}
: CS1 maint: date auto-translated (link) CS1 maint: multiple names: mga may-akda (link)